Middle East and Africa Generic Drugs Market

Middle East and Africa Generic Drugs Market Size

The Middle East and Africa Generic Drugs Market is projected to grow from USD 35.23 billion in 2025 to USD 37.56 billion in 2026 and reach USD 62.62 billion by 2034, registering a CAGR of 6.6% during the forecast period from 2026 to 2034.

Generic Drugs refer to the pharmaceuticals that comprise bioequivalent, lower-cost alternatives to branded medications, approved for therapeutic use following patent expiration. These drugs play a pivotal role in expanding access to essential treatments across a region marked by fragmented healthcare systems and high out-of-pocket expenditures. With rising non-communicable disease prevalence and strained public budgets, generic drugs have become a cornerstone of sustainable healthcare delivery across the region.

MARKET DRIVERS

Escalating Burden of Chronic Diseases

The increasing prevalence of non-communicable diseases (NCDs) such as diabetes, hypertension, and cardiovascular disorders is a primary catalyst for generic drug demand in the MEA region. According to the World Health Organization, NCDs account for 37% of all deaths in the African region, a figure projected to surpass infectious diseases by 2030. This surge necessitates long-term pharmacological management, placing immense pressure on healthcare financing. As urbanization and aging populations amplify NCD incidence, the reliance on cost-effective generic therapies will deepen across public and private care settings.

Government-Led Price Control and Substitution Policies

Public health authorities across MEA are actively promoting generic drug adoption through regulatory mandates and economic incentives. By institutionalizing generics as the default treatment option, governments are reshaping prescribing behavior and enhancing medicine affordability at scale.

MAREKT RESTRAINTS

Persistent Concerns Over Quality and Bioequivalence

Despite regulatory advancements, skepticism regarding the efficacy and safety of generic drugs remains widespread among healthcare providers and patients in the MEA region. Additionally, counterfeit generics, estimated to constitute 19% of the pharmaceutical market in sub-Saharan Africa as per the WHO, further blur the distinction between legitimate and illicit products. Without robust post-market monitoring and transparent approval processes, quality concerns will continue to impede full generic integration.

Fragmented Regulatory Landscapes and Approval Delays

The absence of harmonized drug regulation across MEA countries creates significant barriers to the timely registration and distribution of generic medications. In Angola and Cameroon, manufacturers must undergo separate clinical bioequivalence studies for each country, despite identical therapeutic claims, increasing development costs, and delaying market entry. The Gulf Cooperation Council (GCC) has made strides in unifying standards, yet discrepancies persist in labeling, packaging, and import licensing. This regulatory fragmentation discourages multinational generic firms from investing in smaller markets, limiting competition and sustaining higher prices for essential medicines.

MARKET OPPORTUNITES

Expansion of Local Manufacturing Capacity

Several MEA nations are prioritizing domestic pharmaceutical production to reduce import reliance and strengthen medicine security. The African Continental Free Trade Area (AfCFTA) further enables regional scale-up by reducing trade barriers. With over 70% of medicines in Africa currently imported, as per the UN Economic Commission for Africa, local generic production represents a transformative opportunity for self-reliance and economic development.

Digital Health Integration and E-Pharmacy Growth

The rapid proliferation of digital health platforms is creating new distribution channels for generic drugs across MEA. Mobile-based medicine ordering is particularly effective in rural areas where physical pharmacy access is limited. Startups are leveraging AI-driven inventory systems to supply generics to clinics at reduced margins. This digital transformation enhances transparency, reduces distribution costs, and accelerates patient access to affordable treatments.

MARKET CHALLENGES

Supply Chain Instability and Cold Chain Deficiencies

The distribution of temperature-sensitive generic drugs, including biosimilars and certain antibiotics, is severely constrained by inadequate logistics infrastructure in MEA. Power outages further exacerbate storage risks. Poor road networks in countries like Chad and South Sudan delay deliveries by weeks, leading to stockouts. Without investment in cold chain resilience and last-mile delivery systems, the integrity of the generic drug supply remains compromised.

Currency Volatility and Import Dependency

Most MEA countries rely on imported active pharmaceutical ingredients (APIs) and finished dosage forms, making generic drug pricing vulnerable to foreign exchange fluctuations. This forced local manufacturers such as Fidson Healthcare to delay production cycles and reduce output. Similarly, Sudan’s economic crisis has disrupted procurement, with public hospitals reporting shortages of generic antihypertensives and antidiabetics in 2023. Without local API production or hedging mechanisms, currency instability continues to threaten the affordability and availability of essential generic therapies across the region.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Type Insights

The branded generic drugs segment held the largest share of the MEA generic drugs market at 63.5% of total sales in 2024, as reported by the African Journal of Pharmacy and Pharmacology. This dominance stems from higher consumer and prescriber trust associated with established brand names, even when the active ingredients are identical to unbranded counterparts. In markets where regulatory oversight is perceived as inconsistent, physicians frequently prescribe branded generics to ensure quality assurance. These products benefit from marketing investments, packaging differentiation, and distribution networks that mirror originator brands.

The pure generic drugs segment is the fastest-growing and is projected to expand at a CAGR of 9.4% from 2025 to 2033. This growth is driven by aggressive cost-containment policies and the rise of centralized tenders that prioritize the lowest-priced bioequivalent. Additionally, digital pharmacies like MyDawa are listing pure generics with transparent pricing, increasing consumer access and acceptance in urban and semi-urban populations.

By Application Insights

The cardiovascular segment dominated the MEA generic drugs market by application and captured 27.6% of total consumption in 2024, according to the Eastern Mediterranean Health Journal. This leadership is primarily attributed to the escalating prevalence of hypertension, ischemic heart disease, and stroke across the region. As per the World Health Organization, cardiovascular diseases account for 35% of all non-communicable disease deaths in the Eastern Mediterranean region, with Egypt and Sudan recording some of the highest hypertension rates globally. Additionally, regional formularies prioritize generic statins and beta-blockers, ensuring their widespread availability in both public clinics and private pharmacies.

The oncology segment is experiencing the fastest growth, with a projected CAGR of 11.2% between 2025 and 2033. This acceleration is fueled by rising cancer incidence, improved diagnosis rates, and the expiration of patents on high-cost biologic drugs. According to the International Agency for Research on Cancer, over 1 million new cancer cases were diagnosed in Africa in 2022, a figure expected to double by 2040 due to aging populations and lifestyle changes. The introduction of generic versions of trastuzumab, rituximab, and imatinib has significantly reduced treatment costs by up to 80% in some cases, enabling broader access in public hospitals. Furthermore, partnerships such as the Africa Joint Procurement Platform have pooled demand to negotiate lower prices for generic chemotherapy agents, improving affordability across low- and middle-income nations.

COUNTRY LEVEL ANALYSIS

Egypt Generic Drugs Market Insights

Egypt stood as the largest national market for generic drugs in the Middle East and Africa at 22.6% of the regional value in 2024. The country’s position is anchored in its robust domestic pharmaceutical industry. Egypt’s domestic pharmaceutical industry is highly developed, producing most of the local generics. Major manufacturers include Amoun, EIPICO, and Pharco. Additionally, Egypt also serves as a regional export hub, supplying generics to Libya, Sudan, and the Horn of Africa.

Saudi Arabia Drugs Market Insights

Saudi Arabia is contributing majorly to the MEA generic drugs market, which is driven by large-scale government procurement and healthcare modernization under Vision 2030. The Ministry of Health’s Saudi Pharmaceutical Procurement Strategy has prioritized cost-effective treatments for diabetes, hypertension, and hepatitis C. Furthermore, the establishment of the King Abdullah Medical City’s centralized pharmacy system has enhanced distribution efficiency. Thus, Saudi Arabia’s demand for affordable generics continues to expand, supported by regulatory reforms and digital health integration.

South Africa Drugs Market Insights

South Africa is distinguished by its relatively advanced regulatory framework and healthcare infrastructure. The country’s generic penetration rate exceeds 85% in the public sector, where the National Department of Health procures medicines through the tenders managed by the State Pharmaceuticals Corporation, as per the South African Health Products Regulatory Authority (SAHPRA). Chronic disease burden is a key driver: over 4.5 million people live with diabetes, and 7.5 million are on antiretroviral therapy, primarily using generic regimens. The Medicines and Related Substances Act mandates generic substitution, reinforcing affordability. However, supply chain inefficiencies and stockouts in rural clinics remain challenges. Despite this, South Africa remains a hub for biosimilar development, with companies like Aspen Pharmacare producing generic versions of oncology and antiviral drugs for both domestic and pan-African distribution n.

Arab Emirates Drugs Market Insights

United Arab Emirates is functioning as a high-income gateway for pharmaceutical distribution across the Gulf and East Africa. The country’s advanced cold chain logistics and e-prescription systems have facilitated the distribution of temperature-sensitive generics, including insulin and biologics. Moreover, free zones like Dubai Science Park are attracting multinational generic manufacturers to establish regional headquarters, enhancing supply resilience. With a growing expatriate population and rising NCD prevalence, the UAE’s demand for cost-effective therapies is poised for sustained growth.

Kenya Drugs Market Insights

Kenya is emerging as a pharmaceutical hub for East and Central Africa due to its relatively stable regulatory environment and growing local production capacity. The country’s Medical Stores Department procures generics through international tenders. Local manufacturers such as Universal Corporation and Kenafric Laboratories have expanded output to meet regional demand under the African Continental Free Trade Area. Additionally, Kenya’s integration of generics into the Linda Mama maternal health program and UHC pilot initiatives has broadened access in underserved areas. With mobile health platforms improving last-mile delivery, Kenya is positioning itself as a model for scalable generic drug deployment in sub-Saharan Africa.

KEY MARKET PLAYERS

Some of the companies that are currently playing a dominant role in the MEA generic drugs market profiled in the report are Ranbaxy Laboratories, Ltd, Actavis, Mylan, Inc., Industries, Ltd., Dr. Reddy’s Laboratories, Par Pharmaceutical, Inc., Sandoz International GmbH, Hospira, Inc., Apotex, Inc., Watson Pharmaceuticals, Ltd., and Teva Pharmaceuticals.

TOP LEADING PLAYERS IN THE MARKET

Hikma Pharmaceuticals

Hikma Pharmaceuticals, headquartered in Amman, Jordan, is a leading force in the MEA generic drugs market, with a deep-rooted presence across the Middle East, North Africa, and sub-Saharan Africa. The company operates advanced manufacturing facilities in Jordan, Saudi Arabia, and the United States, enabling it to supply a broad portfolio of generic injectables, oral solids, and respiratory products. In recent years, Hikma has intensified its focus on complex generics, including generic versions of branded respiratory therapies and oncology injectables, to differentiate from price-driven competitors. While primarily centered on MEA, Hikma has expanded its footprint in the Asia-Pacific region through strategic distribution partnerships in Australia and Southeast Asia, particularly for its generic analgesics and cardiovascular drugs.

Aspen Pharmacare

Aspen Pharmacare, based in South Africa, is a dominant player in the African pharmaceutical landscape, with a strong emphasis on generic and specialty medicines. The company manufactures over 250 generic products, including antiretrovirals, cardiovascular agents, and oncology biosimilars, distributed across 100 countries. Aspen has strategically positioned itself as a supplier of off-patent branded generics, maintaining long-term supply contracts with African governments and global health agencies such as the Global Fund. In the Asia-Pacific region, Aspen has established a presence in Australia and India through licensing agreements for its generic erythropoietin and insulin analogs. The company also partnered with Thailand’s Government Pharmaceutical Organization in 2024 to transfer technology for biosimilar production, reinforcing its role as a bridge between African and Asian generic drug ecosystems.

Pharco Corporation

Pharco Corporation, an Egyptian multinational, has emerged as a key architect of local pharmaceutical self-reliance in the MEA region, producing over 200 generic formulations across cardiovascular, anti-infective, and CNS categories. The company operates one of the largest integrated manufacturing complexes in North Africa, with FDA- and WHO-GMP-compliant facilities that support exports to 35 countries. Pharco has invested heavily in R&D to develop fixed-dose combinations tailored to regional disease patterns, such as hypertension and hepatitis C. While its core market remains Egypt and the Arab world, Pharco has extended its reach into the Asia-Pacific through distribution alliances in Pakistan and Bangladesh, where demand for affordable chronic disease medications is rising. In early 2024, it initiated a technology transfer program with a Sri Lankan pharmaceutical firm to co-produce generic antibiotics, signaling its ambition to become a South-South pharmaceutical collaborator.

TOP STRATEGIES USED BY KEY MARKET PARTICIPANTS

Key players in the MEA generic drugs market are deploying multifaceted strategies to consolidate their regional dominance and expand into adjacent geographies. Major approaches include vertical integration to secure API supply, investment in complex and biosimilar generics to avoid commoditization, expansion of local manufacturing to bypass import barriers, strategic public-sector tenders to ensure volume stability, and technology transfer partnerships to enhance regional production capacity. Companies are increasingly focusing on regulatory harmonization across MEA nations to accelerate approvals. Digital engagement through e-pharmacies and telemedicine platforms is being leveraged to improve distribution reach. Additionally, firms are forming cross-border alliances to pool procurement and navigate currency volatility, ensuring sustainable access to essential medicines in high-demand therapeutic areas.

COMPETITION OVERVIEW

The competitive dynamics of the MEA generic drugs market are shaped by a blend of regional champions, multinational subsidiaries, and emerging local manufacturers vying for dominance in a fragmented yet high-potential landscape. Incumbents like Hikma and Aspen leverage established distribution networks and regulatory expertise to maintain strongholds in their respective subregions. Competition is intensifying as companies differentiate through product complexity, manufacturing quality, and supply chain resilience rather than price alone. Regulatory disparities and infrastructure gaps create entry barriers, favoring firms with localized production and government partnerships. The rise of biosimilars and digital health integration is redefining competitive advantage, while public health imperatives continue to drive consolidation and strategic collaboration across national borders in pursuit of medicine security.

RECENT MARKET DEVELOPMENTS

• In February 2023, Hikma Pharmaceuticals inaugurated a new inhalation manufacturing facility in Amman, Jordan, with an annual capacity of 20 million units, enabling localized production of generic respiratory drugs and reducing dependency on imports across the Middle East and North Africa.
• In July 2023, Aspen Pharmacare finalized the divestment of its European generics portfolio to focus capital and R&D resources on high-growth African and Asia-Pacific markets, reinforcing its strategic pivot toward regional self-reliance and specialty generic development.
• In October 2023, Pharco Corporation launched a domestically produced generic version of sofosbuvir under the brand name Pharco C, reducing hepatitis C treatment costs by 90% and expanding access to over 500,000 patients across Egypt and neighboring countries.
• In March 2024, Hikma Pharmaceuticals entered a co-development agreement with Cipla to launch generic inhaled therapies for chronic respiratory diseases, targeting markets in the Middle East and Southeast Asia with combined R&D and distribution capabilities.
• In May 2024, Aspen Pharmacare initiated a technology transfer partnership with Thailand’s Government Pharmaceutical Organization to enable local production of biosimilar erythropoietin, strengthening its presence in the Asia-Pacific region while supporting regional medicine security.

MARKET SEGMENTATION

This Middle East and Africa generic drugs market report has been segmented and sub-segmented into the following categories.

By Type

• Pure Generic Drugs
• Branded Generic Drugs

By Application

• The Central Nervous System (CNS)
• Cardiovascular
• Dermatology
• Oncology
• Respiratory
• Others

By Country

• KSA
• UAE
• Israel
• The rest of the GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• Rest of MEA